Scientific Abstracts (Table). Receiver operating characteristic curves showed that M-DAS28, DAS28 (CRP) and RAPID3 had higher predictive value (area under the curve) than CDAI or SDAI for radiographic progression at M12 and M24 (Table) . There was no impact of treatment arm on predictors of radiographic outcomes. Conclusions: In this post hoc analysis, disease activity scores at baseline according to M-DAS28, DAS28 (CRP) and RAPID3 were good predictors of radiographic progression at M12 and M24 and were more predictive than other measures of disease activity tested, with M-DAS28 demonstrating the greatest degree of prediction. Background: Rheumatoid Arthritis (RA) onset may occur at any age and peaks in the fifth decade. Because the mean age of general population is continually increasing and since older age could impact on outcomes, late-onset RA (LORA) will probably become a relevant issue for health care system in the next future. A better characterization of LORA could help rheumatologist in the therapeutic decision-making process tailored on the individual patient. Objectives: To investigate the relationship between age at disease onset and clinical, ultrasonographic and functional outcomes. . At baseline biological, functional and ultrasonographic data were recorded. The following items were compared at baseline and after 12 months from diagnosis: DAS28 CRP remission rate, functional disability using the Health Assessment Questionnaire (HAQ), power doppler (PWD) score, Methotrexate (MTX) treatment, use of glucocorticoids (GCs).
Background: Rheumatoid Arthritis (RA) onset may occur at any age and peaks in the fifth decade. Because the mean age of general population is continually increasing and since older age could impact on outcomes, late-onset RA (LORA) will probably become a relevant issue for health care system in the next future. A better characterization of LORA could help rheumatologist in the therapeutic decision-making process tailored on the individual patient. Objectives: To investigate the relationship between age at disease onset and clinical, ultrasonographic and functional outcomes. Methods: Early RA (ERA) patients fulfilling 2010 ACR/EULAR, with available clinical ad ultrasonographic follow-up of at least 1 year, who consecutively attended our Early Arthritis Clinic between 2009-2014, were retrospectively analyzed. Patients were pooled into 3 groups by age at RA onset: <45 years (young-onset RA [YORA] group 1), 45 to 60 years (intermediate-onset RA [IORA] group 2), and >60 years (late-onset RA [LORA] group 3). At baseline biological, functional and ultrasonographic data were recorded. The following items were compared at baseline and after 12 months from diagnosis: DAS28 CRP remission rate, functional disability using the Health Assessment Questionnaire (HAQ), power doppler (PWD) score, Methotrexate (MTX) treatment, use of glucocorticoids (GCs).
Results:
The main baseline demographic and disease characteristics of the whole sample of ERA (n=223) and the 3 age groups-YORA (46), IORA (81) and LORA (96)-are summarised in Table 1 . Age at RA-onset was independently associated with DAS28 CRP remission at 1 year (Table 2) . Conclusions: In a cohort of ERA, older age at disease onset is associated with a more active pattern disease at the beginning but with a greater probability of DAS28 CRP remission at 1 year. Figure) . Analyses used published results when available or patient-level data when not (i.e., for Leiden; and for OPERA CRP analyses). Frequency of RP over one year was determined by category of MBDA score (low, moderate [30-44] , high on a scale of 1-100) at the start of the year for four cohorts and by category of MBDA score at the end of the year for AMPLE cohorts (as published). RP was defined using the threshold for change in total modified Sharp score ( mTSS) specific to each study (2 to >5 TSS units). Positive and negative predictive values (PPV and NPV) were determined for each study by comparing patients with high MBDA score (>44), DAS28-(ESR/CRP) (>5.1 or >4.09) or CRP (>3 mg/dL) vs. those in a not-high category. Relative risk (RR) for RP was determined for each study, and in a meta-analysis of the non-overlapping patient groups with MBDA scores available at the start of the year (Leiden, SWEFOT Year 1 and OPERA Year 1).
Results of multivariate analyses and analyses that combined MBDA score with other risk factors for RP were summarized. Results: The 6 study cohorts included patients receiving csDMARDs alone or with adalimumab, infliximab or abatacept. Overall rates of RP were 10-26%. In each study, RP was most frequent among patients with a high vs. not-high MBDA score (>44 vs. ≤44). For high MBDA scores, NPVs were 93-97% and PPVs were 18-32%, with RR values of 3.6-9.5 (P=0.002 to <0.0001) ( Figure) . In a meta-analysis of the Leiden, SWEFOT Year 1 and OPERA Year 1 cohorts, RR was 5.1 (P<0.0001) for MBDA categories, and 1.4 (P=0.23) and 1.6 (P=0.01) for categories of DAS28-CRP or CRP, respectively. Previously published multivariate analyses in the Leiden and SWEFOT Year 1 cohorts showed that MBDA score was an independent predictor of RP compared with other predictors. In the Leiden cohort, MBDA score was the strongest predictor and high MBDA score discriminated between high and low risk for RP among patients with high SJC (>5) or high DAS28-CRP, with PPV as high as 57%. Conclusions: RA is a disease that increases fatigue, depressive symptoms and widespread pain.DAS 28 scores were higher due to the increased pain scores and tender joint count that are subjective parameters in female RA patients. Pain scores in females are significantly higher than in males, and pain exacerbated by central sensitization pathway in women may lead to sleep disorders and fatigue, but not increase depressive symptoms.
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[1] The role of central nervous system in the generation and main tance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Lee YC, Nassikas NJ, Clauw DJ. Arthritis Research and Therapy (2011) Background: Some studies revealed an association of Power Doppler (PD) ultrasound (US)-detected residual synovitis (PDUSS) and risk of relapse and radiographic progression (RP), in individual patients in rheumatoid arthritis (RA). However, the longitudinal relationship between clinical remission and repeated US residual lesions during follow-up is not so well-known. Objectives: The aim of this study was to evaluate the ability of PDUSS in consecutive examinations to predict unfavorable outcome (i.e. clinical relapse or RP) at 1 year. Methods: RA patients ≥18 years fulfilling 2010 ACR-EULAR criteria, treated with synthetic or biologic (b) DMARDs and in clinical remission (DAS28-ESR<2.6 and no clinically active synovitis) for less than 6 months, were included in the longitudinal prospective SONORE study (ClinicalTrials.gov identifier: NCT02618954). Clinical and biological characteristics of patients were collected at baseline, and every 3 months during 1 year. RA treatment had to be stable during follow-up. A standard US examination on 40 joints for the presence of synovial hypertrophy and PD signal was performed by an independent investigator blinded to clinical and radiographic data at each visit during 1 year. Presence of US synovitis was defined by a PD signal≥1 in at least one joint. Radiographs of hands, wrists and feet were scored at baseline and 1 year. Outcome measures: RP was defined by an increase ≥1 point of the modified total Sharp score. A relapse was defined by a DAS28>3.2 at ≥1 follow-up visits AND a change of DMARDs, excluding change due to safety issues; or an increase in the DMARD or Corticosteroid (CS) dosage (≥5mg/d). Baseline variables, including PDUSS and its persistence during the follow-up, were assessed for their association with time to progression to unfavorable outcome using univariate then stepwise multivariate Cox regression analyses to obtain adjusted HRs. Results: The 115 included patients had a mean (SD) age of 58.9 (±12.8) years, mean disease duration of 9.3 (±9.3) years, a mean duration of remission of 2.1 (±2.3) months. 74.8% were female, 79.1% of the patients were anti-CCP positive, 51.4% had erosive disease. The mean DAS28-ESR was 2.03 (±0.63). 59.2% received methotrexate, 59.9% bDMARD and 11.7% CS. PDUSS was detected in ≥1 joint in 75 patients (72.1%) at baseline. 41/75 (54.7%) had persistence of at least one PDUSS during the follow-up. 26 (23.2%) had a relapse (after a mean duration of 9.1 (±2.6) months) or a RP at 1 year. In multivariate analysis, persistence of at least one PDUSS during the follow-up (HR=5.24 [1.74-22.5], p=0.009) and baseline number of tender joints (HR=1.32 [0.95-1.68], p=0.052) were predictors of relapse or RP at 1 year. Duration of remission, other baseline US findings including baseline PDUSS, autoantibodies, and erosive disease had no additional predictive value. Conclusions: Persistence of a PDUSS during the follow-up, rather than baseline PDUSS, predicts unfavorable outcome at 1 year in RA patients in clinical remission. This suggests that initial US findings are not sufficient to justify therapeutic change, but that the persistence of a residual PDUSS requires careful follow-up, and might even potentially merit strategy adaptation. Objectives: To assess the factors associated with RR achievement in patients (pts) with RA while non-biological DMARDs using. Methods: A cohort of 174 pts with RA (50.6% with early RA) was prospectively assessed at baseline and 2 years by the Disease Activity Score (DAS28) and the Sharp-van der Heijde Score (SHS). Mean age at inclusion was 52.0±0.91 yrs, disease duration -51.3±4.82 month. 82.7% of the pts were women; 62.6% were positive for rheumatoid factor (RF) and 75.9% -for antibodies against cyclic citrullinated peptides (aCCP). Pts were treated with methotrexate (MTX) (mean dose -11.6±0.29 mg/w, n=157), leflunomide (LF) (19.2±0.28 mg/d, n=95), sulfasalazine (SS) (2 g/d, n=76) or combination of DMARDs (CD) (n=74). After 2 yrs of DMARDs therapy 41 pts (23.5%) reached RR ( SHS≤0.5). No one pts using low dose of MTX (7.5 mg/week) achieved remission so they were excluded from further analysis. According to RR achievement in 2 yrs pts were divided into
